Zhu et al., 2022 - Google Patents
Palladium nanoplate-based IL-6 receptor antagonists ameliorate cancer-related anemia and simultaneously inhibit cancer progressionZhu et al., 2022
- Document ID
- 18379402478651988087
- Author
- Zhu J
- Fu Q
- Wang S
- Ren L
- Feng W
- Wei S
- Zhang Z
- Xu Y
- Ganz T
- Liu S
- Publication year
- Publication venue
- Nano Letters
External Links
Snippet
In recent years, targeted therapies and immunotherapeutics, along with conventional chemo- and radiotherapy, have greatly improved cancer treatments. Unfortunately, in cancer patients, anemia, either as a complication of cancer progression or as the result of cancer …
- 208000007502 Anemia 0 title abstract description 156
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Near-infrared light irradiation induced mild hyperthermia enhances glutathione depletion and DNA interstrand cross-link formation for efficient chemotherapy | |
| Peng et al. | Tumor microenvironment responsive drug‐dye‐peptide nanoassembly for enhanced tumor‐targeting, penetration, and photo‐chemo‐immunotherapy | |
| Roma-Rodrigues et al. | Targeting tumor microenvironment for cancer therapy | |
| Dominiak et al. | Communication in the cancer microenvironment as a target for therapeutic interventions | |
| Guo et al. | Intravesical in situ immunostimulatory gel for triple therapy of bladder cancer | |
| Binnemars-Postma et al. | Nanomedicine strategies to target tumor-associated macrophages | |
| Chen et al. | Reversibly stabilized polycation nanoparticles for combination treatment of early-and late-stage metastatic breast cancer | |
| Kamaly et al. | Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles | |
| Yu et al. | Enhanced cancer-targeted drug delivery using precoated nanoparticles | |
| Pascal et al. | Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response | |
| Su et al. | Dual-sensitive PEG-sheddable nanodrug hierarchically incorporating PD-L1 antibody and zinc phthalocyanine for improved immuno-photodynamic therapy | |
| Dianzani et al. | Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment | |
| Sun et al. | Cargo-free nanomedicine with pH sensitivity for codelivery of DOX conjugated prodrug with SN38 to synergistically eradicate breast cancer stem cells | |
| Zhu et al. | Palladium nanoplate-based IL-6 receptor antagonists ameliorate cancer-related anemia and simultaneously inhibit cancer progression | |
| Sano et al. | Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo | |
| Bai et al. | Octreotide-conjugated core-cross-linked micelles with pH/redox responsivity loaded with etoposide for neuroendocrine neoplasms therapy and bioimaging with photoquenching resistance | |
| Huang et al. | Altered cell cycle arrest by multifunctional drug-loaded enzymatically-triggered nanoparticles | |
| Zheng et al. | Multifunctional nanomodulators regulate multiple pathways to enhance antitumor immunity | |
| Pei et al. | Bioactive Vanadium Disulfide Nanostructure with “Dual” Antitumor Effects of Vanadate and Gas for Immune-Checkpoint Blockade-Enhanced Cancer Immunotherapy | |
| Lu et al. | Zinc–Iron Bimetallic Peroxides Modulate the Tumor Stromal Microenvironment and Enhance Cell Immunogenicity for Enhanced Breast Cancer Immunotherapy Therapy | |
| Yu et al. | Glucose transporter 1-mediated transcytosis of glucosamine-labeled liposomal ceramide targets hypoxia niches and cancer stem cells to enhance therapeutic efficacy | |
| Lin et al. | Janus silica nanoparticle-based tumor microenvironment modulator for restoring tumor sensitivity to programmed cell death ligand 1 immune checkpoint blockade therapy | |
| Qu et al. | Precise photodynamic therapy by midkine nanobody-engineered nanoparticles remodels the microenvironment of pancreatic ductal adenocarcinoma and potentiates the immunotherapy | |
| Zhou et al. | Nanotechnology reprogramming metabolism for enhanced tumor immunotherapy | |
| Lu et al. | Camouflaged Nanoreactors Mediated Radiotherapy-Adjuvant Chemodynamic Synergistic Therapy |